Related Experiment Video
Updated: Jun 6, 2025
An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient
Published on: November 30, 2022
The impact of dexamethasone on short- and long-term mortality in hospitalized COVID-19 patients: a retrospective
Jian Zhao1, Hui Hua Jiang1, Hong Hong Wan1
1Department of Emergency, Shanghai 10th People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Background:
Dexamethasone has been widely used in treating severe COVID-19 patients due to its anti-inflammatory properties. However, its long-term impact on mortality remain unclear.
Objective:
To evaluate the effect of dexamethasone on short-term (28-day) and long-term (1-year) mortality in hospitalized COVID-19 patients and to explore its efficacy across different respiratory support.
Methods:
A retrospective cohort study was conducted using the MIMIC-IV (v3.0) database. A total of 576 confirmed COVID-19 patients were included, with 288 patients receiving dexamethasone and 288 not receiving it, matched by propensity scores. Survival analyses assessed the impact of dexamethasone on mortality, and subgroup analyses were performed based on the type of respiratory support received.
Results:
After propensity score matching, dexamethasone treatment was associated with reduced mortality at both 28 days (adjusted HR 0.67, 95% CI 0.46-0.99, P = 0.045) and 1 year (adjusted HR 0.66, 95% CI 0.47-0.92, P = 0.014). Subgroup analysis revealed differential treatment effects by respiratory support type (P for interaction = 0.001 at 28 days and 0.004 at 1 year). The survival benefit was most pronounced in patients receiving NIV (28-day adjusted HR 0.15, 95% CI 0.05-0.42, P < 0.001) and significant in those receiving IMV (28-day adjusted HR 0.62, 95% CI 0.39-0.99, P = 0.045), while no significant benefit was observed in patients receiving oxygen therapy alone.
Conclusion:
This retrospective study suggests that dexamethasone treatment was associated with reduced mortality in hospitalized COVID-19 patients, particularly in those receiving NIV or IMV. These findings add to the evidence supporting dexamethasone use in severe COVID-19 patients requiring respiratory support.
More Related Videos
09:36Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:20Comparing the Survival Analysis of Two or More Groups
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:21Skeletal Muscle Relaxants: Adverse Effects
Unlike...
01:21Cancer Survival Analysis
01:19Respiratory Assessment: Purpose and Indications
Objectives and Importance:
The primary goal of respiratory assessment is to evaluate patients at early risk of clinical deterioration. Since respiratory distress often precedes other signs of declining health, breathing patterns and sounds become a...